WASHINGTON (Reuters) - U.S. drug reviewers have questioned Pfizer Inc.'s data showing the pain reliever Celebrex was as effective as an older drug in treating juvenile rheumatoid arthritis, a summary ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results